Cargando…

Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products

Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and deaths in the world. Treatment is largely based on lifestyle modification, which is difficult to achieve in most patients. Progression of simple...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernando, Dinali H., Forbes, Josephine M., Angus, Peter W., Herath, Chandana B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834322/
https://www.ncbi.nlm.nih.gov/pubmed/31614491
http://dx.doi.org/10.3390/ijms20205037
_version_ 1783466468937039872
author Fernando, Dinali H.
Forbes, Josephine M.
Angus, Peter W.
Herath, Chandana B.
author_facet Fernando, Dinali H.
Forbes, Josephine M.
Angus, Peter W.
Herath, Chandana B.
author_sort Fernando, Dinali H.
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and deaths in the world. Treatment is largely based on lifestyle modification, which is difficult to achieve in most patients. Progression of simple fatty liver or steatosis to its severe form non-alcoholic steatohepatitis (NASH) and liver fibrosis has been explained by a ‘two-hit hypothesis’. Whilst simple steatosis is considered the first hit, its transformation to NASH may be driven by a second hit. Of several factors that constitute the second hit, advanced glycation end products (AGEs), which are formed when reducing-sugars react with proteins or lipids, have been implicated as major candidates that drive steatosis to NASH via the receptor for AGEs (RAGE). Both endogenous and processed food-derived (exogenous) AGEs can activate RAGE, mainly present on Kupffer cells and hepatic stellate cells, thus propagating NAFLD progression. This review focuses on the pathophysiology of NAFLD with special emphasis on the role of food-derived AGEs in NAFLD progression to NASH and liver fibrosis. Moreover, the effect of dietary manipulation to reduce AGE content in food or the therapies targeting AGE/RAGE pathway on disease progression is also discussed.
format Online
Article
Text
id pubmed-6834322
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68343222019-11-25 Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products Fernando, Dinali H. Forbes, Josephine M. Angus, Peter W. Herath, Chandana B. Int J Mol Sci Review Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and deaths in the world. Treatment is largely based on lifestyle modification, which is difficult to achieve in most patients. Progression of simple fatty liver or steatosis to its severe form non-alcoholic steatohepatitis (NASH) and liver fibrosis has been explained by a ‘two-hit hypothesis’. Whilst simple steatosis is considered the first hit, its transformation to NASH may be driven by a second hit. Of several factors that constitute the second hit, advanced glycation end products (AGEs), which are formed when reducing-sugars react with proteins or lipids, have been implicated as major candidates that drive steatosis to NASH via the receptor for AGEs (RAGE). Both endogenous and processed food-derived (exogenous) AGEs can activate RAGE, mainly present on Kupffer cells and hepatic stellate cells, thus propagating NAFLD progression. This review focuses on the pathophysiology of NAFLD with special emphasis on the role of food-derived AGEs in NAFLD progression to NASH and liver fibrosis. Moreover, the effect of dietary manipulation to reduce AGE content in food or the therapies targeting AGE/RAGE pathway on disease progression is also discussed. MDPI 2019-10-11 /pmc/articles/PMC6834322/ /pubmed/31614491 http://dx.doi.org/10.3390/ijms20205037 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fernando, Dinali H.
Forbes, Josephine M.
Angus, Peter W.
Herath, Chandana B.
Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products
title Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products
title_full Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products
title_fullStr Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products
title_full_unstemmed Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products
title_short Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products
title_sort development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834322/
https://www.ncbi.nlm.nih.gov/pubmed/31614491
http://dx.doi.org/10.3390/ijms20205037
work_keys_str_mv AT fernandodinalih developmentandprogressionofnonalcoholicfattyliverdiseasetheroleofadvancedglycationendproducts
AT forbesjosephinem developmentandprogressionofnonalcoholicfattyliverdiseasetheroleofadvancedglycationendproducts
AT anguspeterw developmentandprogressionofnonalcoholicfattyliverdiseasetheroleofadvancedglycationendproducts
AT herathchandanab developmentandprogressionofnonalcoholicfattyliverdiseasetheroleofadvancedglycationendproducts